Drugs / SOLENGEPRAS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT06006247 | Sep 2023 → Jan 2025 | Parkinson disease | Cerevance Beta, Inc. | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06553027 | Sep 2024 → Aug 2026 overdue | Parkinson disease | Cerevance | Active not recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT05635461 Comparator | Oct → Nov 2022 | Parkinson disease | Cerevance Beta, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03657030 Comparator | Sep 2018 → Mar 2019 | — | Cerevance Beta, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04191577 Comparator | Dec 2019 → Nov 2021 | Parkinson disease | Cerevance Beta, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Cerevance Beta, Inc. | Results Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease cerevance.com ↗
Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today presented positive Phase 2 results of solengepras, a novel, non-dopaminergic GPR6 inhibitor in development as an adjunctive treatment for Parkinson’s disease. |
| 2025-04-01 | Cerevance Beta, Inc. | Results Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025 cerevance.com ↗
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mechanism of action |
| 2024-10-21 | Cerevance Beta, Inc. | Results Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinical Medicine cerevance.com ↗
Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, has published the full results from the Phase 2 clinical trial of solengepras, in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery Science Suite. |
| 2022-03-31 | Cerevance Beta, Inc. | Results Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism cerevance.com ↗
At the high dose, CVN424 showed a 1.3-hour improvement in OFF time compared to placebo (p=0.042) at four weeks. |
| 2019-04-30 | Cerevance Beta, Inc. | Results Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424 cerevance.com ↗
The clinical study successfully met its primary endpoint of safety in healthy volunteers. |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOLENGEPRAS | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802203 ↗ |
| Known as | CVN424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06553027 ↗ |
| Modality | Small molecule | — CHEMBL4802203 ↗ |
| Route | Oral | “Study drug will be self-administered each morning as an oral suspension.” NCT04191577 ↗ |